6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)nicotinic acid | 1187187-03-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)nicotinic acid
• 英文别名: 6-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]pyridine-3-carboxylic acid
• CAS: 1187187-03-6
• 化学式: C₁₃H₁₀BNO₅
• 分子量: 271.037
• InChiKey: WVARFNLPFXGESG-UHFFFAOYSA-N

物化性质

• 沸点：
  490.6±55.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.79
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  88.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)nicotinic acid 、 二乙胺 在 N,N-二异丙基乙胺 、 chlorotri(pyrrolidin-1-yl)phosphonium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以94%的产率得到N,N-diethyl-6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)nicotinamide
  参考文献：
  名称：

  Boron-Containing Small Molecules as Anti-Inflammatory Agents

  摘要：

  化合物和治疗抗炎症状况的方法被披露。

  公开号：

  US20150291629A1
• 作为产物：
  描述：

  n-butyl 6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)nicotinate 在 CD-1 female mouse plasma 作用下， 生成 6-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)nicotinic acid
  参考文献：
  名称：

  Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application

  摘要：

  PDE4 inhibitors are a validated approach as anti-inflammatory agents but are limited by systemic side effects including emesis. We report a soft-drug strategy incorporating a carboxylic ester group into boron-containing PDE4 inhibitors leading to the discovery of a series of benzoxaborole compounds with good potency (for example IC(50) = 47 nM of compound 2) and low emetic activity. These compounds are intended for dermatological use further limiting possible systemic side effects. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.010

文献信息

• BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS
  申请人：Akama Tsutomu

  公开号：US20120214765A1

  公开（公告）日：2012-08-23

  Compounds and methods of treating anti-inflammatory conditions are disclosed.

  本发明公开了治疗抗炎症状况的化合物和方法。
• Boron-containing small molecules as anti-inflammatory agents
  申请人：Anacor Pharmaceuticals, Inc.

  公开号：US08039450B2

  公开（公告）日：2011-10-18

  Compounds and methods of treating anti-inflammatory conditions are disclosed.

  本发明揭示了治疗抗炎症状况的化合物和方法。
• Boron-Containing Small Molecules as Anti-Inflammatory Agents
  申请人：ANACOR PHARMACEUTICALS, INC.

  公开号：US20150291629A1

  公开（公告）日：2015-10-15

  Compounds and methods of treating anti-inflammatory conditions are disclosed.

  化合物和治疗抗炎症状况的方法被披露。
• Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application
  作者：Yong-Kang Zhang、Jacob J. Plattner、Tsutomu Akama、Stephen J. Baker、Vincent S. Hernandez、Virginia Sanders、Yvonne Freund、Richard Kimura、Wei Bu、Karin M. Hold、Xiao-Song Lu

  DOI：10.1016/j.bmcl.2010.02.010

  日期：2010.4

  PDE4 inhibitors are a validated approach as anti-inflammatory agents but are limited by systemic side effects including emesis. We report a soft-drug strategy incorporating a carboxylic ester group into boron-containing PDE4 inhibitors leading to the discovery of a series of benzoxaborole compounds with good potency (for example IC(50) = 47 nM of compound 2) and low emetic activity. These compounds are intended for dermatological use further limiting possible systemic side effects. (C) 2010 Elsevier Ltd. All rights reserved.